Guía completa de terapia con péptidos 2026

FDA Approves Lilly's Foundayo — the First GLP-1 Pill You Can Take Any Time Without Food Restrictions

The FDA approved orforglipron (Foundayo), Eli Lilly's once-daily oral GLP-1 receptor agonist for obesity. Unlike Novo Nordisk's oral Wegovy, Foundayo has no food or water restrictions, marking a major convenience leap for the 100+ million Americans with obesity.

FDA Approves ICOTYDE — the First Oral Peptide That Targets IL-23 for Psoriasis

Johnson & Johnson's ICOTYDE (icotrokinra) is the first oral peptide to precisely block the IL-23 receptor, offering complete skin clearance in a once-daily pill for moderate-to-severe plaque psoriasis. Approved March 18, 2026, it could replace injections as first-line systemic therapy.

3rd Peptide-Based Therapeutics Summit Opens in Boston as Industry Hits Inflection Point

The 3rd Peptide-Based Therapeutics Summit convenes in Boston in April 2026, bringing together researchers, pharma executives, and regulators as the peptide drug market is projected to reach $54.6 billion. Key themes include oral delivery breakthroughs, AI-driven peptide design, and the FDA's shifting regulatory posture.

Unnatural Products Raises $45M to Build Oral Macrocyclic Peptides for 'Undruggable' Targets

Santa Cruz biotech Unnatural Products closed a $45M Series B led by The Venture Collective, following a potential $1.7B Novartis collaboration. The company engineers synthetic macrocyclic peptides that can be taken orally and hit targets that traditional small molecules and antibodies cannot reach.

Review

Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.

Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial

The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.

Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.

Peptide Publicus Editorial·Yesterday·1 min read

Informational

Son seguros los péptidos: lo que dice la investigación clínica

¿Son seguros los péptidos? Analizamos lo que dice la investigación clínica sobre el perfil de seguridad de los péptidos terapéuticos, incluyendo datos de ensayos publicados en PubMed, regulaciones de la AEMPS, COFEPRIS y ANMAT, y los riesgos reales que debes conocer.